Jonathan D. Campbell, PhD, MS

Discussions about drug pricing require consideration of values and preferences, according to Jonathan D. Campbell, PhD, chief science officer of the National Pharmaceutical Council.

As pharmaceutical R&D policies evolve, the authors argue it is crucial to embed American patient values in reimbursement deliberations and frameworks.

This commentary explains why comparing a launch price with a value-based price from a cost-effectiveness analysis requires further examination.

This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.

We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.

Even small changes in average copayment for long-term controller asthma medications can result in significant reductions in medication use and increases in healthcare services.